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Background: The Estrogen Receptor alpha (ERα) is the key transcriptional regulator in luminal breast cancer and is
therefore the main target for adjuvant treatment of this subtype. Luminal gene signatures are dictated by the
transcriptional capacities of ERα, which are a direct consequence of the receptors binding preference at specific
sites on the chromatin. The identification of ERα binding signatures on a genome-wide level has greatly enhanced
our understanding of Estrogen Receptor biology in cell lines and tumours, but the technique has its limitations with
respect to its applicability in limited amounts of tumour tissue.
Results: Here, we present a refinement of the ChIP-seq procedures to enable transcription factor mapping on
limited amounts of tissue culture cells as well as from a limited amount of tumor tissue derived from core needle
biopsies. Our approach uses a carrier that can be removed prior to DNA amplification and sequencing.
Conclusion: We illustrate the applicability of this refined technology by mapping the ERα genome-wide chromatin
binding landscape in core needle biopsy material from primary breast tumours. With this, our refined technology
permits for a high-resolution transcription factor mapping even from clinical samples.Background
Breast cancer is the most common diagnosed malig-
nancy in women, with over 1.4 million new cases world-
wide annually [1]. 75% of all breast cancers are from the
luminal subtype [2] for which tumour growth is thought
to be dependent on the activity of the Estrogen Receptor
alpha (ERα). This growth-dependency renders this path-
way the main target for adjuvant endocrine treatment in
luminal breast cancer.
The physiological behaviour of the ERα involves bind-
ing of the receptor to its natural ligand estradiol, after
which the receptor associates to the chromatin, recruits
its coregulators and alters the transcriptional activity of
responsive genes, leading to increased cell proliferation
and tumour growth. In endocrine treatment of breast
cancer, the activation of the receptor can be inhibited
through multiple ways, each of which resulting in an* Correspondence: Jason.Carroll@cruk.cam.ac.uk
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reproduction in any medium, provided the orinhibition of ERα-driven cell proliferation. Even though
these endocrine intervention therapies greatly increase
the disease-free survival and overall survival of breast
cancer patients [3], resistance to treatment is commonly
observed. This resistance can be mediated through a
multitude of different mechanisms, including differential
expression of kinases [4,5], coregulators [3,6] and trans-
membrane receptors [7,8].
Importantly, it is becoming apparent that mechanisms
of resistance may result from intrinsic effects on ERα/
chromatin interactions, as shown both in cell lines [9,10]
and in tumour samples [11]. Since the ERα/chromatin
interactome directly determines the estradiol-mediated
effects on gene expression [12], distinct binding patterns
may be a key-defining factor for deviating gene expres-
sion patterns as well [13]. A major hurdle to assay such
transcription factor/chromatin interactions, is the fre-
quently very limited starting material due to the minimal
amount of tissue that is obtained during diagnostic
work-up.
Recently approaches have been described to map his-
tone modifications in a limited amount of startingtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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for transcription factors. Similarly, new methods for
amplification of limited material have been described
[15], but these assume that sufficient DNA was recov-
ered from the ChIP to enable amplification in the first
place. One of the major technical limitations has been
enriching sufficient DNA (via ChIP) from limited
starting material. This problem has been addressed using
‘carrier chromatin’ [16], a strategy that is not amenable
to global sequencing approaches. Here, we describe a
procedure to enhance transcription factor ChIP-seq by
incorporating a modified carrier method to enable ChIP-
seq from limited starting material. We apply this method
to map the ERα/chromatin interactome in as few as
10,000 tissue culture cells and apply this technology to
map the ERα chromatin binding landscape in core nee-
dle biopsy samples from breast cancer patients.
Results and discussion
Carrier selection for small cell number ChIPs
To optimize the Chromatin Immunoprecipitation (ChIP)
procedure from a limited amount of cells, we utilized
the well-characterized (ERα-positive and Progesterone
Receptor-positive) breast cancer cell line MCF7. MCF7
cells have been widely applied for ChIP-seq applications,
and multiple datasets are publicly available to be used asFigure 1 Carrier-optimized ChIP-seq in MCF7 cells. A. ChIP-qPCR on pS
glycogen, mRNA/histones, glycogen/mRNA/histones). Data were normalize
deviation from triplicate measurements. B. Genome browser snapshot of E
10,000 cells without (top) or with mRNA/histones carrier (middle). Data was
Genomic coordinates and tag count are indicated. C. Heatmap visualization
peak region within a 5 kb window around the peak. All peaks for the 20*1
both 10,000 cells-conditions were plotted in identical order.a reference. Proliferating MCF7 cells from a sub-confluent
10 cm dish were harvested, after which the total amount
of cells were counted. The lysate from 10,000 cells was
used for ChIP. Initially a focused ERα ChIP-real time PCR
approach was taken, using the well-studied pS2 promoter
region. ERα ChIP was performed using standard methods
[17], but in the absence of carrier, no enrichment from the
ChIP sample was observed (Figure 1A). In addition, two
independent carriers were tested: glycogen and mRNA/
histones. The rationale was to test carriers that were either
inert (glycogen; not having any effect on the chromatin
nor sequencing procedure) or had a composition that
could be removed from the sample (mRNA and histones;
to be removed by RNAse A and Proteinase K). The car-
riers were added to the lysate mixture before antibody-
conjugate addition. Glycogen proved to have a small, but
not significant increase in ChIP efficiency, when using the
pS2 promoter region. The addition of recombinant his-
tones and random human mRNA led to a significant in-
crease of ERα signal at the pS2 promoter (Figure 1A).
This enhanced enrichment was achieved both by an in-
creased ChIP efficiency for specific signal as well as a de-
crease of the nonspecific background binding (Additional
file 1: Figure S1). Combining the two carrier procedures
resulted in a decreased signal as compared to only adding
mRNA/histones.2/TFF1 promoter for ERα with differential carrier conditions (none,
d over negative control region and input. Bars show standard
Rα ChIP-seq, depicting the pS2/TFF1 promoter and enhancer region for
compared to a saturated ERα ChIP-seq from 20*106 cells (bottom).
of ERα ChIP-seq data, depicting all binding events centred on the
06 cells ChIP-seq condition were ranked on intensity, and the data from
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moter was indicative of increased ChIP efficiency, this
cannot be generalized towards all ERα/chromatin inter-
actions. Therefore, the ERα ChIP-samples were further
processed and prepared for sequencing. Only the two
extreme conditions (no carrier versus mRNA/Histones
carrier) were sequenced and compared to a publicly avail-
able dataset of proliferating MCF7 cells, performed on
~20 million cells [10]. The carrier mRNA and histone
were degraded prior to amplification of enriched ChIP
DNA. An example of difference in binding capacity in the
presence and absence of carrier mRNA/histones is shown
in Figure 1B and all binding events are illustrated as a
heatmap in Figure 1C. Importantly, we ranked all ERα
binding peaks observed in the sample with ~20 million
cells and found that ~60% of these were recapitulated
when using the mRNA and histones as carrier from
10,000 cells. This is a substantial improvement compared
to ERα ChIP-seq without carrier, where only signal was
detected at ~20% of peaks. Heatmap visualisations and
quantifications indicated that peak calling on 10,000 cells
with RNA/histones carrier provided comparable signal
intensity distributions as the saturated ChIP. This in
contrast to the 10,000 cells analysis without carriers
(Additional file 2: Figure S2) where mainly background
was found. Grouping the ChIP distributions on the basis
of signal intensities showed that peaks with high-intensity
signal under the RNA/histones carrier ChIP conditions,
consistently provided high signal distributions for the sat-
urated ChIP, and vice versa (Additional file 3: Figure S3).
No subsets of false-positive and false-negative regions
were observed (Additional file 3: Figure S3). Interestingly,
the dynamic range of signal intensity as detected in the
saturated ChIP was dampened under the carrier condi-
tions (Additional file 3: Figure S3A). Cumulatively, these
data show that the addition of carrier chromatin facilitates
transcription factor ChIP-seq from 10,000 cells, without
negatively effecting the amplification or global fidelity of
the process.
In order to confirm the biological validity of the ERα
binding events mapped using mRNA/histone as carrier
for ChIP-seq from 10,000 cells, we integrated the
binding information with estrogen (E2)-mediated gene
expression profiles. For all E2-regulated genes, we deter-
mined whether our altered ChIP protocol enabled the
identification of proximal ERα as compared to the satu-
rated ChIP (Figure 2). We used a publically available
gene expression microarray dataset, from MCF7 cells
treated for 6 hours with E2 [13] and found 1,821 tran-
scripts up-regulated and 1,812 down-regulated by E2. A
window of 20 kb around the transcription start-site was
applied to determine proximal ERα binding (which has
previously been shown to be the optimal window be-
tween ERα binding events and promoters of targetgenes [12]). For the saturated ChIP-seq, approximately
60% of all E2 up- and downregulated genes had a prox-
imal ERα binding event (Figure 2A), which is consistent
with our previous report [13]. Using the ERα binding
events discovered from 10,000 cells with the mRNA/his-
tones as carrier, we found that 38% of the E2 up-
regulated genes had an adjacent ERα binding event
(Figure 2A), a figure under-represented because of the
fewer ERα binding events in this category. We also ranked
the strongest gene-proximal ERα binding events from the
mRNA/histone carrier-sample based on tag count, resulting
in binding at well-described ERα target genes, including
TFF1, RARA, GREB1 and XBP1 (Figure 2B).
Carrier-ChIP from core needle biopsies of human breast
tumours
Given the findings that mRNA/histone carrier appeared
to assist ChIP-seq from limited cell numbers, we applied
this approach to clinically relevant samples. We chose to
study core needle biopsy samples from breast cancer pa-
tients, since they represent clinically available, but limited
material that would be appropriate for our approach.
These samples were all positive for Estrogen Receptor, as
determined by immunohistochemistry (Additional file 4:
Table S2). We tested the two carrier conditions independ-
ently; 1. glycogen 2. mRNA in combination with recombin-
ant Histone 2B. ERα ChIP-seq was performed in all core
needle biopsies. When using glycogen as a carrier, a small
level of enrichment was observed from the biopsy samples,
as exemplified at multiple binding sites (Figure 3A). Im-
portantly, in the presence of mRNA/histone carriers, the
enrichment at both the example regions and globally, was
significantly increased. This resulted in 669 ERα peaks in
the presence of glycogen and 3,366 peaks in the presence
of mRNA/histone carrier for two biopsies with directly
comparable clinical parameters (Additional file 4: Table
S2). Importantly, in the presence of mRNA/histone carrier,
ERα ChIP-seq signal was comparable to the level observed
in the cell line (Figure 3A), suggesting that the presence of
the carrier enables increased ERα ChIP-seq signal, even
when applied to limited samples obtained from core needle
biopsies.
ERα binding events are rarely found at promoters (5%)
and the majority of binding sites is normally enriched at
introns and distal intergenic regions [18]. We analysed
the binding site localizations and found that the mRNA/
histones assisted ChIP-seq showed comparable genomic
distributions compared to cell line data (Figure 3B).
Motif analyses were performed for the mRNA/histone
assisted ChIP condition (Figure 3C). As expected, ER
DNA binding motifs were the most strongly enriched
motifs.
Since ERα is the driving transcription factor in luminal
breast cancer, we interrogated the genes proximal to the
Figure 2 Proximal Estradiol-responsive genes and carrier ERα ChIP-seq enrichment. A. Estradiol up- (white) and down-regulated (black)
genes were interrogated for proximal ERα binding events under saturated conditions with 20*106 cells (right), as well as ChIP-seq on 10,000 cells
without (left) and with mRNA/histones carrier (middle). The percentage of E2-reponsive genes with a proximal ERα binding site is shown. B. ERα
binding events with mRNA/histones carriers were ranked and proximal E2-upregulated genes were determined for the top 10 highest intensity
binding sites. Heatmap indicates tag count.
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previously identified as basal or luminal gene signatures
in independent cohorts of breast cancer patients [2]
(Figure 3D). For the glycogen carrier condition, none of
these hallmark genes were found to have a proximal
ERα binding event for any of the tumour samples tested
(data not shown). For the mRNA/histone-assisted condi-
tion, an enrichment of luminal genes was found over
basal-signature genes (Figure 3D). Expression of these
signature genes with proximal ERα binding events was
found to correlate with a favourable outcome after endo-
crine treatment in a meta-analysis of breast cancer patients
with ERα-positive disease [19] (Figure 3E), indicating that
our carrier ChIP-seq protocol enabled us to identify direct
ERα target genes with clinical implications from core nee-
dle biopsy samples.
Conclusion
The genome-wide assessment of ERα/chromatin interac-
tions has been performed in tissue culture cell lines [18]
and primary breast cancer tissue [11]. Even though
ChIP-seq is a very powerful technology to delineate tran-
scription factor-chromatin interactions and to identify
specific locations of histone marks on a genome-wide
level, the technology does have its intrinsic limitations.
The availability of a specific antibody and applicable for
immunoprecipitation from formaldehyde-fixed material
are major limitations. In addition, there are potential is-
sues related to epitope masking. Another major limita-
tion of ChIP-seq analyses is the need for a certain
amount of starting material. Reports have described
ChIP-seq analyses on histone marks on limited startingmaterial [14], but these represent relatively stable cova-
lent interactions, as compared to the dynamic and un-
stable interactions between transcription factors and
chromatin. In directed ChIP analyses, the benefit of
carrier during the immunoprecipitation procedure has
proven to be substantial [16]. In that method, non-
relevant chromatin (e.g. drosophila DNA), is added as a
carrier during the procedure, in order to enhance the
enrichment from the limited but relevant cellular mater-
ial. While this approach can be applied for qPCR-ChIP, it
is not readily applicable for ChIP-seq, which will sequence
all DNA, regardless of the species, resulting in substantial
dilution of the relevant enriched DNA. How the addition
of the carriers exactly enhances the ChIP procedure on a
molecular level still needs to be resolved. Most likely, the
bulky material of the carrier helps to retain the small
amounts of relevant chromatin throughout the isolation
procedure. In addition, it might prove an additional bene-
fit of blocking nonspecific antibody/protein interactions,
thereby increasing substrate specificity of the antibody in
the reaction to reduce background signal.
Here, we introduce a novel mode of carrier-assisted
Chromatin Immunoprecipitation that can be applied to
transcription factor mapping by ChIP-seq. The enrich-
ment from limited cellular material is enhanced by the
addition of mRNA and recombinant histone protein,
which function as a carrier. Importantly, both compo-
nents of the carrier can subsequently be removed and
provide an approach that is cost effective, easily applied
and applicable in next-generation sequencing reactions.
We applied this approach to map ERα in 10,000 asyn-
chronous MCF7 cells, which results in an improved
Figure 3 Carrier ChIP-seq analyses on breast tumour core needle biopsies. A. Genome browser snapshots of ERα ChIP-seq on MCF7 cells
(black) and breast cancer core needle biopsy samples with glycogen (blue) or mRNA/histones (red) as carriers. Tag count is shown on the Y-axis.
Genomic locations are indicated. B. Genomic distributions of ERα binding events in MCF7 cells (top) and breast tumour biopsy samples with
mRNA/histones as carrier (bottom). C. Motif analysis of ERα binding events on a core needle biopsy sample, with mRNA/histones as carrier.
Indicated are the top 3 enriched motifs and p-values. D. Luminal enrichment for ERα carrier ChIP-seq genes. Genes, identified as ‘luminal’ or
‘basal’ signatures by Perou et al. [2] were analysed for proximal ERα binding events. Enrichment of ‘luminal’ over ‘basal’ genes was found. E.
Genes, identified in D., were tested for correlation with recurrence-free survival, using Estrogen Receptor positive samples from a meta-analysis of
breast cancer patients [19]. Expression of identified genes correlated with a favourable outcome after endocrine treatment.
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this recapitulated ~60% of the signal observed when
performing ERα ChIP-seq in saturating numbers of cells,
these possessed all the expected characteristics of robust
ERα binding events. The dynamic range of the ChIP sig-
nal intensity was dampened under carrier conditions,
possibly implying that weaker ChIP enrichment regions
are enhanced in our method. Furthermore, as a proof-of-
principle, we applied our carrier-assisted ChIP protocol
to limited material derived from core needle biopsy sam-
ples, isolated from breast cancer patients. Again, the
presence of the mRNA/histone carrier resulted inincreased ERα ChIP-seq signal, allowing for discovery of
clinically and biologically relevant ERα regulatory do-
mains from these samples. Several approaches have been
recently described [15,20] that enhance amplification
from limited DNA. Although these are powerful
methods, they assume that there is sufficient DNA
enriched by ChIP, but currently, methods do not exist
that enable the ChIP enrichment from limited material
for integration with these novel amplification approaches.
We believe that our modified carrier ChIP-method im-
proves the ability for purifying transcription factor-
associated DNA from limited material, such as tumour
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ChIP approach with the novel amplification methods for
greater ChIP-seq fidelity and signal from primary mater-
ial, potentially permitting high-resolution transcription
factor mapping even from clinical samples.Methods
Chromatin Immunoprecipitations
ChIP was performed as described before [17], but
with a number of modifications. During the Immuno-
precipitation, 100 μg/ml glycogen (Invitrogen) or 20 μg/
ml recombinant histone 2B (M2505S; New England
Biolabs) and 1 μg/ml human mRNA (Invitrogen) was
added as carriers for the ChIP. During the entire pro-
cedure, non-sticky eppendorf tubes were used (13-698-
794; Fisher Scientific). 5 μg antibody used was raised
against ERα (SC-543; Santa Cruz), conjugated to 50 μl
protein A Dynabeads (Invitrogen). After immunoprecip-
itation, ten RIPA washes were performed (samples
transferred to a fresh eppendorf during the last wash),
followed by one TBS wash and reverse crosslinking, as
described [17].Solexa sequencing
ChIP DNA was amplified as described [17], using 18
PCR amplification cycles. Sequences generated by the
Illumina GAIIx genome analyzer (using 36-bp reads)
were aligned against NCBI Build 36.3 of the human gen-
ome using MAQ (http://maq.sourceforge.net/) with de-
fault parameters. Peaks were called using model-based
analysis for ChIP-Seq (MACS)[21] run using default pa-
rameters. Read counts and duplication rates for all cell
line and tumor samples are shown in Additional file 5:
Table S1. The number of clonal reads in the carrier sam-
ple was higher and may be a result of increased duplica-
tion reads of remaining non-ligated adapters.Motif analysis, heatmaps and genomic distributions of
binding events
ChIP-seq data snapshots were generated using the Inte-
grative Genome Viewer IGV 2.1 (www.broadinstitute.
org/igv/). Motif analyses were performed through the
Cistrome (cistrome.org), applying the SeqPos motif tool
[22]. The genomic distributions of binding sites were
analysed using the cis-regulatory element annotation
system (CEAS) [23]. The genes closest to the binding
site on both strands were analysed. If the binding region
is within a gene, CEAS software indicates whether it is
in a 50UTR, a 30UTR, a coding exon, or an intron. Pro-
moter is defined as 3 kb upstream from RefSeq 50 start.
If a binding site is >3 kb away from the RefSeq transcrip-
tion start site, it is considered distal intergenic.Tumour tissue handling
Tissue for ChIP-seq analyses was from four newly diag-
nosed breast cancer patients who were treated at the
Netherlands Cancer Institute. Three specimens were col-
lected under a prospective pre-operative endocrine therapy
study approved by the institutional ethics committee.
These patients provided written informed consent. Also
one sample, taken from anonymous left over material,
which would be discarded otherwise, was used. Since we
are using anonymous, coded leftover material which is not
traced back to the patients and does therefore not interfere
with care and/ or prognosis, no ethical approval is required
according to Dutch legislation [the Medical Research In-
volving Human Subjects Act; http://www.ccmo-online.nl/
main.asp?pid=10&sid=30&ssid=51) and our institutional
medical ethical review board. This conforms as described
[24]. Three biopsies (14-gauge, 15 μm thick) were taken
from each tumour, two of which where frozen with liquid
nitrogen and one was formalin-fixed for direct clinical as-
sessment. Tumour cell percentage was determined using
Hematoxylin and Eosin (H&E), and tissue was only used
for ChIP-seq analysis when tumour cell percentage was
higher then 50%. All samples stained positive for Estrogen
Receptor. Further information on the tumor samples and
patient characteristics can be found in Additional file 4:
Table S2.
Gene expression analyses and survival data
Genes with an ERα binding site within 20 kb from the
transcription start site were interrogated. Estradiol-
responsive genes were used from a publically available
database [13]. Luminal and basal genes were previously
identified [2]. For survival analyses, a publically available
meta-analysis was used. ERα positive-tumours were se-
lected from breast cancer patients who received adjuvant
endocrine treatment [19].
Data deposition
All genomic data is deposited at ArrayExpress under the
accession number E-MTAB-1534.
Additional files
Additional file 1: Figure S1. Carrier ChIP QPCR enrichment for the pS2
promoter and negative control region. ChIP enrichment was calculated
as percentage over input, both for the pS2-positive control (left panel)
and for the negative control region (right panel). The RNA/histones
carrier increases signal as the pS2 positive control region, while it
diminishes signal at the negative control site.
Additional file 2: Figure S2. Heatmap visualizations and signal
quantifications for the three ChIP conditions. MACS peak caller was
applied for sequencing data from samples without carrier (A), with the
RNA/histones carriers (B) and the saturated ChIP (C). For each peak
calling dataset, the corresponding genomic locations were tested for all
three sequencing runs, as visualized in heatmaps (arrow head indicated
centre of the peak, scale = 5 kb) and quantified in the 2D graphs.
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http://www.biomedcentral.com/1471-2164/14/232Additional file 3: Figure S3. Peak subgroups and correlations between
carriers/saturated ChIP samples. MACS peak caller was applied for
sequencing data from samples with the RNA/histones carriers (A) and the
saturated ChIP (B). Peaks were subgrouped in ‘high’ (I), ‘medium’ (II) and
‘low’ (III), and raw signal intensity for the RNA/histones carriers and the
saturated ChIP sequencing runs was analyzed. For each of the subsets,
the corresponding genomic locations were visualized in heatmaps (arrow
head indicated centre of the peak, scale = 5 kb) and quantified in the 2D
graphs.
Additional file 4: Table S2. Tumor characteristics, hormonal status and
menopausal state.
Additional file 5: Table S1. Sequencing reads and duplication rate.
Competing interests
The authors declare no competing financial interests.
Authors’ contributions
WZ carried out the experiments and analyzed the data. RK provided the
tissue samples and participated in the design of the study. SL participated in
the design of the study, coordinated the clinical aspects of the study and
helped to draft the manuscript. ER provided the tissue samples and helped
in design the clinical aspects of the study. JW performed the pathological
assessment of the tissue samples and helped drafting the manuscript. JC
and WZ conceived, designed and coordinated the study and drafted the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
We thank James Hadfield for Solexa sequencing, Gordon Brown, Rory Stark
and Suraj Menon for bioinformatic help. We thank Sara Dietz for help on the
initial development of the protocol.
Funding
We acknowledge the support of The University of Cambridge, Cancer
Research UK, the Dutch Cancer Society, A Sisters Hope and The Netherlands
Cancer Institute. J.S.C. is supported by an ERC Starting Grant (242664) and W.
Z. is supported by a KWF Dutch Cancer Society fellowship.
Author details
1Department of Molecular Pathology, The Netherlands Cancer Institute,
Amsterdam, the Netherlands. 2Department of Pathology, The Netherlands
Cancer Institute, Amsterdam, the Netherlands. 3Department of Surgical
Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
4Department of Medical Oncology, The Netherlands Cancer Institute,
Amsterdam, the Netherlands. 5Cancer Research UK, Cambridge Research
Institute, Li Ka Shing Centre, Robinson Way, Cambridge CB2 0RE, UK.
6Department of Oncology, University of Cambridge, Cambridge CB2 OXY, UK.
Received: 5 September 2012 Accepted: 22 March 2013
Published: 8 April 2013
References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of
worldwide burden of cancer in 2008: GLOBOCAN 2008. International
journal of cancer Journal international du cancer 2010, 127(12):2893–2917.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR,
Ross DT, Johnsen H, Akslen LA, et al: Molecular portraits of human breast
tumours. Nature 2000, 406(6797):747–752.
3. Osborne CK, Bardou V, Hopp TA, Chamness GC, Hilsenbeck SG, Fuqua SA,
Wong J, Allred DC, Clark GM, Schiff R: Role of the estrogen receptor
coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast
cancer. J Natl Cancer Inst 2003, 95(5):353–361.
4. Holm C, Rayala S, Jirstrom K, Stal O, Kumar R, Landberg G: Association
between Pak1 expression and subcellular localization and tamoxifen
resistance in breast cancer patients. J Natl Cancer Inst 2006, 98(10):671–680.
5. Michalides R, Griekspoor A, Balkenende A, Verwoerd D, Janssen L, Jalink K,
Floore A, Velds A, van’t Veer L, Neefjes J: Tamoxifen resistance by a
conformational arrest of the estrogen receptor alpha after PKA
activation in breast cancer. Cancer Cell 2004, 5(6):597–605.
6. Redmond AM, Bane FT, Stafford AT, McIlroy M, Dillon MF, Crotty TB, Hill AD,
Young LS: Coassociation of estrogen receptor and p160 proteins predictsresistance to endocrine treatment; SRC-1 is an independent predictor of
breast cancer recurrence. Clinical cancer research: an official journal of the
American Association for Cancer Research 2009, 15(6):2098–2106.
7. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R:
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2
/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004,
96(12):926–935.
8. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J:
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal
antibody, inhibits basal and activated Her2 ectodomain cleavage in
breast cancer cells. Cancer Res 2001, 61(12):4744–4749.
9. Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T, Zhang X,
Carroll JS, Rhodes DR, Liu XS, et al: Growth factor stimulation induces a
distinct ER(alpha) cistrome underlying breast cancer endocrine
resistance. Genes Dev 2010, 24(19):2219–2227.
10. Hurtado A, Holmes KA, Ross-Innes CS, Schmidt D, Carroll JS: FOXA1 is a key
determinant of estrogen receptor function and endocrine response. Nat
Genet 2011, 43(1):27–33.
11. Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ,
Brown GD, Gojis O, Ellis IO, Green AR, et al: Differential oestrogen receptor
binding is associated with clinical outcome in breast cancer. Nature 2012,
481(7381):389–393.
12. Fullwood MJ, Liu MH, Pan YF, Liu J, Xu H, Mohamed YB, Orlov YL, Velkov S,
Ho A, Mei PH, et al: An oestrogen-receptor-alpha-bound human
chromatin interactome. Nature 2009, 462(7269):58–64.
13. Zwart W, Theodorou V, Kok M, Canisius S, Linn S, Carroll JS: Oestrogen
receptor-co-factor-chromatin specificity in the transcriptional regulation
of breast cancer. EMBO J 2011, 30(23):4764–4776.
14. Adli M, Zhu J, Bernstein BE: Genome-wide chromatin maps derived from
limited numbers of hematopoietic progenitors. Nat Methods 2010,
7(8):615–618.
15. Shankaranarayanan P, Mendoza-Parra MA, Walia M, Wang L, Li N, Trindade
LM, Gronemeyer H: Single-tube linear DNA amplification (LinDA) for
robust ChIP-seq. Nat Methods 2011, 8(7):565–567.
16. O’Neill LP, VerMilyea MD, Turner BM: Epigenetic characterization of the
early embryo with a chromatin immunoprecipitation protocol applicable
to small cell populations. Nat Genet 2006, 38(7):835–841.
17. Schmidt D, Wilson MD, Spyrou C, Brown GD, Hadfield J, Odom DT: ChIP-
seq: using high-throughput sequencing to discover protein-DNA
interactions. Methods 2009, 48(3):240–248.
18. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS,
Keeton EK, Fertuck KC, Hall GF, et al: Genome-wide analysis of estrogen
receptor binding sites. Nat Genet 2006, 38(11):1289–1297.
19. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, Szallasi Z: An
online survival analysis tool to rapidly assess the effect of 22,277 genes
on breast cancer prognosis using microarray data of 1,809 patients.
Breast Cancer Res Treat 2010, 123(3):725–731.
20. Adli M, Bernstein BE: Whole-genome chromatin profiling from limited
numbers of cells using nano-ChIP-seq. Nat Protoc 2011, 6(10):1656–1668.
21. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, Nusbaum
C, Myers RM, Brown M, Li W, et al: Model-based analysis of ChIP-Seq
(MACS). Genome Biol 2008, 9(9):R137.
22. He HH, Meyer CA, Shin H, Bailey ST, Wei G, Wang Q, Zhang Y, Xu K, Ni M,
Lupien M, et al: Nucleosome dynamics define transcriptional enhancers.
Nat Genet 2010, 42(4):343–347.
23. Ji X, Li W, Song J, Wei L, Liu XS: CEAS: cis-regulatory element annotation
system. Nucleic Acids Res 2006, 34(Web Server issue):W551–W554.
24. van Diest PJ: No consent should be needed for using leftover body
material for scientific purposes. For. BMJ 2002, 325(7365):648–651.
doi:10.1186/1471-2164-14-232
Cite this article as: Zwart et al.: A carrier-assisted ChIP-seq method for
estrogen receptor-chromatin interactions from breast cancer core
needle biopsy samples. BMC Genomics 2013 14:232.
